Spyre Therapeutics, Inc. (SYRE) quarterly cash flow statement — complete operating, investing & financing history
| Cash from Operations | -57.54M | -44.58M | -37.12M | -46.56M | -40.99M | -37.2M | -29.42M | -62.25M | -28.54M | -31.04M | -34.6M | -16.64M |
| Operating CF Margin % | - | -49.26% | - | - | - | - | - | - | - | - | - | -2419.04% |
| Operating CF Growth % | -40.37% | -19.84% | -26.16% | 25.2% | -43.63% | -19.86% | 14.96% | -274.02% | -61.86% | -71.09% | -129.61% | 19.49% |
| Net Income | -69M | -51.83M | -11.18M | -36.72M | -44.77M | -56.3M | -69.03M | -38.84M | -43.86M | -63.18M | -40.11M | -217.08M |
| Depreciation & Amortization | 0 | -8.09M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -220K | 0 | 416K |
| Stock-Based Compensation | 0 | 9.81M | 9.57M | 9.38M | 8.86M | 9.22M | 13.1M | 8.68M | 13.84M | 17.27M | 4.79M | 1.91M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1.71M | 0 | 0 |
| Other Non-Cash Items | 11.22M | 7.8M | -41.44M | -10.18M | -4.51M | -917K | 16.16M | -2.94M | -1.99M | 18.66M | 8.68M | 192.14M |
| Working Capital Changes | 244K | -2.27M | 5.94M | -9.04M | -568K | 10.8M | 10.35M | -29.16M | 3.47M | -1.86M | -7.95M | 5.97M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 163K | 1.48M | -1.32M |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -163K | 0 | 0 |
| Change in Payables | -3.21M | 1.45M | 3.75M | 23K | 4.97M | -20.48M | 1.93M | 6.63M | -4.3M | -783K | -1.04M | 661K |
| Cash from Investing | 56.58M | -247.41M | 25M | 79M | -61K | -170.54M | 42.74M | -120.52M | -104.96M | -35.27M | -97.63M | 6.76M |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CapEx % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -15.47M | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 30M | 0 | 0 | 7M | 0 | 0 | 0 | 0 | 0 | 15.47M | 15M | 3.51M |
| Cash from Financing | 12.43M | 312.81M | -4.64M | 731K | 125K | 225.6M | 12.78M | 360K | 172.16M | 163.61M | -12.53M | 209.99M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -8K |
| Equity Issued (Net) | 12.43M | 312.88M | 491K | 731K | -117K | 224.62M | 11.54M | -169.34M | 338.41M | 169.39M | -12.64M | 210M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | -117K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | -69K | -5.13M | 0 | 242K | 979K | 1.24M | 169.7M | -166.25M | -5.79M | 105K | 0 |
| Net Change in Cash | 11.46M | 20.82M | -16.76M | 33.17M | -40.93M | 17.84M | 26.11M | -182.41M | 38.66M | 97.32M | -144.78M | 200.12M |
| Free Cash Flow | -57.54M | -44.58M | -37.12M | -46.56M | -40.99M | -37.2M | -29.42M | -62.25M | -28.54M | -31.04M | -34.6M | -16.64M |
| FCF Margin % | - | -49.26% | - | - | - | - | - | - | - | - | - | -2419.04% |
| FCF Growth % | -40.37% | -19.84% | -26.16% | 25.2% | -43.63% | -19.86% | 14.96% | -274.02% | -61.86% | -71.09% | -129.59% | 19.49% |
| FCF per Share | -0.17 | -0.13 | -0.61 | -0.77 | -0.68 | -0.79 | -0.58 | -1.37 | -0.78 | -1.43 | -8.06 | -4.35 |
| FCF Conversion (FCF/Net Income) | 0.83x | 0.71x | 3.32x | 1.27x | 0.92x | 0.66x | 0.43x | 1.60x | 0.65x | 0.49x | 0.86x | 0.08x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |